卡博桑提尼布单一治疗晚期上腺皮质癌:单臂,第二阶段试验
Matthew T Campbell1, Vania Balderrama-Brondani2, Camilo Jimenez2
1Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The Lancet. Oncology
|April 12, 2024
概括
卡博桑提尼布在先进的上腺皮质癌中显示出有前途的疗效,为这种罕见癌症患者提供可管理的安全性. 目前正在进行进一步的研究,以探索其在组合疗法中的潜力.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮上腺癌 (ACC) 是一种罕见的内分泌恶性瘤,治疗选择有限.
- 米托坦是唯一批准的治疗方法,往往表现出不良的反应率.
- 卡博桑提尼布是一种多酶抑制剂,为ACC提供了潜在的新疗法途径.
研究的目的:
- 为了前性地评估卡博桑提尼布在晚期上腺皮癌患者中的抗瘤活性.
- 评估卡博赞提尼布在这个患者群体中的安全性和耐受性.
- 调查卡博桑提尼布在高级ACC中的药理动力学概况.
主要方法:
- 在MD安德森癌症中心进行了一项单臂二期临床试验.
- 符合条件的成人患者在晚期的ACC接受了口服卡博桑提尼布每天60毫克.
- 主要终点是4个月的无进展生存期,不良事件允许减少剂量.
主要成果:
- 招募了18名患者;13名 (72.2%) 实现了4个月的无进展生存期.
- 中位数无进展生存期为6个月.
- 3级或更严重的与治疗有关的不良事件发生在61%的患者中,脂酶升高和高血压是最常见的. 没有观察到与治疗相关的死亡.
结论:
- 卡博桑提尼布在晚期上腺皮癌中表现出有希望的疗效.
- 该药物表现出可管理和预期的安全性.
- 需要进一步的研究,包括组合疗法,以优化卡博桑提尼布在ACC的使用.
更多相关视频
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.4K
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.1K
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K